| Bioactivity | Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)[1]. |
| Name | Dacomitinib hydrate |
| CAS | 1042385-75-0 |
| Formula | C24H27ClFN5O3 |
| Molar Mass | 487.95 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lau SCM, et al. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs. 2019 Jun;79(8):823-831. |
Dacomitinib hydrate
CAS: 1042385-75-0 F: C24H27ClFN5O3 W: 487.95
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.